Explore the latest in hepatitis C from The JAMA Network, including recent advances in diagnosis and antiviral treatment, prevention of complications, and more.
This case report describes a potentially new association between ocular surface squamous neoplasia and hepatitis C virus in a patient who presented with bleeding from the right eye.
This study describes the experience and virologic outcomes in a cohort of hepatitis C virus–infected homeless and marginally housed adults who were provided access to community-based treatment programs.
This case-matched population study examines the pattern and recurrence rate of de novo hepatocellular carcinoma in patients with liver cirrhosis.
This document review evaluates adherence to the Institute of Medicine standards for limits on commercial conflicts of interest, guideline development, and evaluation of evidence by a 2013 cholesterol management guideline and a 2014 hepatitis C virus management guideline.
This Medical Letter review summarizes background and prescribing information about combination sofosbuvir and velpatasvir, a recently approved oral treatment for all hepatitis C virus genotypes.
This case report describes resolution of porphyria cutanea tarda in patients with hepatitis C following ledipasvir-sofosbuvir combination therapy.
In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.
This Medical News article discusses recent efforts by the Department of Veterans Affairs to extend new hepatitis C treatments to all veterans within its health care system.
This Viewpoint calls for government support for providing direct–acting antiviral treatment to American Indian/Alaska Native population, which is disproportionately infected by hepatitis C virus.
This Viewpoint discusses potential opportunities to advance health care in the US criminal justice system based on recent developments.
This Viewpoint describes how a shortage of health care workers providing treatment for hepatitis C hinders access to treatment, despite progress in drug efficacy and reductions in drug costs.